Fazirsiran for Adults With Alpha-1 Antitrypsin Deficiency Liver Disease: A Phase 2 Placebo Controlled Trial (SEQUOIA).

MLA

Clark, Virginia C., et al. “Fazirsiran for Adults With Alpha-1 Antitrypsin Deficiency Liver Disease: A Phase 2 Placebo Controlled Trial (SEQUOIA).” Gastroenterology, vol. 167, no. 5, Oct. 2024, p. 1008. EBSCOhost, https://doi.org/10.1053/j.gastro.2024.06.028.

APA

Clark, V. C., Strange, C., Strnad, P., Sanchez, A. J., Kwo, P., Pereira, V. M., van Hoek, B., Barjaktarevic, I., Corsico, A. G., Pons, M., Goldklang, M., Gray, M., Kuhn, B., Vargas, H. E., Vierling, J. M., Vuppalanchi, R., Brantly, M., Kappe, N., Chang, T., … Loomba, R. (2024). Fazirsiran for Adults With Alpha-1 Antitrypsin Deficiency Liver Disease: A Phase 2 Placebo Controlled Trial (SEQUOIA). Gastroenterology, 167(5), 1008. https://doi.org/10.1053/j.gastro.2024.06.028

Chicago

Clark, Virginia C, Charlie Strange, Pavel Strnad, Antonio J Sanchez, Paul Kwo, Vitor Magno Pereira, Bart van Hoek, et al. 2024. “Fazirsiran for Adults With Alpha-1 Antitrypsin Deficiency Liver Disease: A Phase 2 Placebo Controlled Trial (SEQUOIA).” Gastroenterology 167 (5): 1008. doi:10.1053/j.gastro.2024.06.028.